

# DECLARATION OF DISCLOSURE

The following faculty members have indicated that during the past 24 months, they have not had any relevant financial relationships or conflicts of interest with commercial interests that may have a direct bearing on the subject matter:

Richard 'Dick' Menzies, MD  
Lisa Chen, MD

The following faculty member presented information on investigational or off-label use of pharmaceuticals or medical devices:

- Richard 'Dick' Menzies, MD (*second and third line tuberculosis drugs: Amikacin, Clofazimine, Delamanid, Fluoroquinolones, Imipenem, Linezolid, Meropenem, Pretomanid [outside the BPaL regimen], Rifabutin*); *other off-label pharmaceuticals: Bedaquiline.*
- Lisa Chen, MD (*second and third line tuberculosis drugs: Amikacin, Clofazimine, Delamanid, Fluoroquinolones, Imipenem, Linezolid, Meropenem, Pretomanid [outside the BPaL regimen], Rifabutin*)

The following faculty member has indicated that within the past 24 months, they have had a relevant financial relationship with a commercial interest which has a direct bearing on the subject matter. All conflicts have been mitigated:

- none

The following planning committee members have indicated that during the past 24 months, they have not had any relevant financial relationships or conflicts of interest with any commercial interest that may have a direct bearing on CME activity:

Lisa Chen, MD  
Kelly Musoke, MPH  
Jeannie Fong